David F. Miller

Diversity and dynamics of the Drosophila transcriptome

James Brown, Nathan Boley, Robert C. Eisman et al. · Nature · 2014 · 820 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Sen Zhang, Rana Anjum, Rachel M. Squillace et al. · Clinical Cancer Research · 2016 · 326 citations · Full text

Medicine, Oncology, Pharmacology +15

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

Wayne W. Chan, Scott Wise, Michael D. Kaufman et al. · Cancer Cell · 2011 · 207 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

Antitumor activity of sorafenib in FLT3-driven leukemic cells

Daniel Auclair, David F. Miller, Victoria Yatsula et al. · Leukemia · 2007 · 169 citations

Medicine, Oncology, Pharmacology +11

Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer

Lyndsay V. Rhodes, Elizabeth C. Martin, H. Chris Segar et al. · Oncotarget · 2015 · 120 citations · Full text

Medicine, Molecular Biology, Oncology +17